Telo Genomics Launches Blood-Based MRD Study for Multiple Myeloma with University of Athens
核心洞察
Telo Genomics (搜索) has initiated a retrospective multiple myeloma (搜索) minimal residual disease (搜索) clinical trial in collaboration with the University of Athens (搜索) as part of its expanding multi-center validation program.
The study will evaluate TeloView MRD (搜索)'s prognostic performance in predicting relapse risk compared to Next-Generation Flow, with access to well-characterized blood samples and three years of patient follow-up data.
TeloView MRD (搜索) is designed to detect disease at high sensitivity down to 1 in 10^7 cells and analyzes 3D genomic architecture of individual MRD cells for enhanced prognostic insights.
Telo Genomics (搜索) Corp. has announced the initiation of a new multiple myeloma (搜索) minimal residual disease (搜索) clinical trial in collaboration with the University of Athens (搜索), marking a significant step in the company's expanding multi-center MRD validation program. The retrospective study is designed to evaluate the clinical utility of Telo's blood-based TeloView MRD (搜索) technology in predicting patient outcomes.
Study Design and Objectives
The University of Athens (搜索) collaboration provides access to well-characterized clinical blood samples with retrospectively available patient outcomes and an average of approximately three years of follow-up data, along with existing serial Next-Generation Flow MRD results. The study aims to assess the prognostic performance of TeloView MRD (搜索) in predicting patients' risk of relapse and compare that performance to NGF, one of the two most widely used MRD assessment approaches in multiple myeloma (搜索) alongside Next-Generation Sequencing.
The cohort includes NGF MRD results available in both blood and bone marrow, supporting a robust comparative dataset for analysis. This comprehensive approach allows researchers to evaluate the relative effectiveness of different MRD detection methods across multiple sample types.
Advanced Technology Platform
TeloView MRD (搜索) is designed to detect disease at high sensitivity in blood, with an expected limit of detection down to 1 in 10^7, meaning it can identify one myeloma cell among 10 million blood cells across different disease stages. In comparison, NGF can reach 10^6 sensitivity in some centers, suggesting TeloView MRD may offer enhanced detection capabilities.
Beyond MRD enumeration, TeloView MRD (搜索) analyzes the 3D genomic architecture of individual MRD cells, which may provide incremental prognostic insight beyond cell counting alone. This advanced analytical approach represents a potential advancement in understanding disease progression at the cellular level.
Expanding Clinical Program
Telo continues to advance its prospective MRD trials with Cleveland Clinic and Jewish General Hospital. The company expects to announce additional retrospective collaborative studies in Q1 2026 as it builds a multi-center, large-scale clinical evidence package to support adoption and demonstrate comparative performance versus established MRD assays.
"We are pleased to be working with Prof. Meletios A. Dimopoulos and Prof. Efstathios Kastritis from the National and Kapodistrian University of Athens (搜索)," said Dr. Sabine Mai, Telo's Co-Founder. "This collaboration is expected to meaningfully strengthen our mission to help redefine MRD-guided clinical practice by bringing more actionable, blood-based insights to physicians and patients."
Clinical Context and Market Impact
Minimal residual disease (搜索) testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. MRD is defined as the small number of cancer cells that remain in the body after treatment, and stratifying MRD cells as in remission or active provides important actionable information for clinicians.
The FDA's Oncologic Drugs Advisory Committee voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma (搜索) therapies, paving the way for faster drug approvals. This regulatory milestone has significant implications for the field, as the MRD global testing market size is expected to reach USD 4.1 billion by 2032.
Multiple Myeloma Disease Burden
Multiple myeloma (搜索) is a challenging and potentially deadly blood cancer that involves plasma cells (搜索), a type of blood cell that helps fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and approximately 180,000 patients receiving treatment at any given time.
The introduction of next-generation therapies, including targeted treatments, has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of Unknown Significance (搜索) and SMM, generally precede the progression to classic symptomatic MM.
While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogeneous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years. Identifying patients who will more rapidly progress to MM remains an important clinical need.
MM treatment includes various combinations of drugs with costs as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. The total addressable market for both MM assays is over 750,000 tests per year in the US.